SCHEMBL6486956

SCHEMBL6486956

CCCCCC=CCCCN(N)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT2 O75908 1/20 0.42
SOAT1 P35610 1/20 0.42
EPHX2 P34913 4/20 0.40
FAAH O00519 2/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
NPC1 O15118 1/20 0.38
JAK2 O60674 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
PPARG P37231 3/20 0.38
PPARA Q07869 3/20 0.38
FFAR1 O14842 2/20 0.38
PPARD Q03181 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486950 1.00 SOAT2 (0.42) SOAT2SOAT1EPHX2FAAHCNR1
SCHEMBL6563180 0.92 SOAT2 (0.41) SOAT2SOAT1EPHX2FAAHCNR1
SCHEMBL6563182 0.92 SOAT2 (0.41) SOAT2SOAT1EPHX2FAAHCNR1
SCHEMBL253120 0.86 NPC1 (0.47) NPC1JAK2RAB9APAX8TP53
SCHEMBL6477122 0.85 EPHX2 (0.41) SOAT2SOAT1EPHX2FAAHCNR1
SCHEMBL6477117 0.85 EPHX2 (0.41) SOAT2SOAT1EPHX2FAAHCNR1
SCHEMBL6488829 0.84 NPC1 (0.50) CNR2NPC1JAK2RAB9APAX8
SCHEMBL6477185 0.84 NPC1 (0.50) CNR2NPC1JAK2RAB9APAX8
SCHEMBL6477702 0.84 NPC1 (0.50) CNR2NPC1JAK2RAB9APAX8
SCHEMBL6487469 0.84 NPC1 (0.50) CNR2NPC1JAK2RAB9APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP SOAT2 603/4885SOAT1 1375/4885EPHX2 307/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP SOAT2 603/4885SOAT1 1375/4885EPHX2 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.